dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Reck, M. |
dc.contributor.author | Ciuleanu, Tudor |
dc.contributor.author | Schenker, M. |
dc.contributor.author | Zurawski, B. |
dc.contributor.author | Menezes, J. |
dc.contributor.author | Felip Font, Enriqueta |
dc.contributor.author | Cobo, Manuel |
dc.date.accessioned | 2022-05-02T11:15:56Z |
dc.date.available | 2022-05-02T11:15:56Z |
dc.date.issued | 2021-10 |
dc.identifier.citation | Reck M, Ciuleanu TE, Cobo M, Schenker M, Zurawski B, Menezes J, et al. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update. ESMO Open. 2021 Oct;6(5):100273. |
dc.identifier.issn | 2059-7029 |
dc.identifier.uri | https://hdl.handle.net/11351/7414 |
dc.description | Immunoteràpia dual; Ipilimumab; Nivolumab |
dc.description.sponsorship | This work was supported by Bristol Myers Squibb (Princeton, New Jersey) (no grant number). Authors received no financial support or compensation for publication of this manuscript. |
dc.language.iso | eng |
dc.publisher | Elsevier |
dc.relation.ispartofseries | ESMO Open;6(5) |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
dc.source | Scientia |
dc.subject | Pulmons - Càncer - Tractament |
dc.subject | Quimioteràpia combinada |
dc.subject.mesh | Carcinoma, Non-Small-Cell Lung |
dc.subject.mesh | /drug therapy |
dc.subject.mesh | Antineoplastic Combined Chemotherapy Protocols |
dc.title | First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in advanced non-small-cell lung cancer: CheckMate 9LA 2-year update |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1016/j.esmoop.2021.100273 |
dc.subject.decs | carcinoma de pulmón de células no pequeñas |
dc.subject.decs | /farmacoterapia |
dc.subject.decs | protocolos de quimioterapia antineoplásica combinada |
dc.relation.publishversion | https://doi.org/10.1016/j.esmoop.2021.100273 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Reck M] Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, LungClinic, Grosshansdorf, Germany. [Ciuleanu TE] Department of Oncology, Institutul Oncologic Prof Dr Ion Chiricuta and UMF Iuliu Hatieganu, Cluj-Napoca, Romania. [Cobo M] Department of Medical Oncology, Unidad de Gestión Clínica Intercentros de Oncología Médica, Hospitales Universitarios Regional y Virgen de la Victoria, IBIMA, Málaga, Spain. [Schenker M] Department of Oncology, SF Nectarie Oncology Center, Craiova, Romania. [Zurawski B] Department of Clinical Oncology, Ambulatorium Chemioterapii, Bydgoszcz, Poland. [Menezes J] Department of Oncology, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil. [Felip E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain |
dc.identifier.pmid | 34607285 |
dc.identifier.wos | 000704803800021 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |